USAntibiotics Awarded FDA National Priority Voucher for Domestic Manufacturing of Critical Antibiotic

Carbonatix Pre-Player Loader

Audio By Carbonatix

BRISTOL, Tenn.--(BUSINESS WIRE)--Oct 22, 2025--

USAntibiotics, the country’s only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced today that the U.S. Food and Drug Administration (FDA) selected its Augmentin XR product for the agency's inaugural Commissioner's National Priority Voucher (CNPV) Program. The new voucher promises a review decision within one to two months following submission of a complete application, collapsing the typical 10 to 12-month FDA timeline.

"This voucher validates what we've known since reopening our Bristol, Tennessee facility in 2021: domestic pharmaceutical manufacturing capacity is a national security imperative, not a luxury," said Patrick Cashman, president, USAntibiotics. "If our doors close, it would take half a decade and hundreds of millions of dollars to rebuild this capability from scratch. That's five years in which America would be completely reliant on adversarial nations for the most prescribed antibiotic in the country. We are enormously grateful that the FDA and policymakers in Washington are prioritizing domestic manufacturing of generic critical medicines."

Augmentin XR is an FDA-approved extended-release combination of amoxicillin and clavulanate potassium. This product is indicated for treatment of community-acquired pneumonia and acute bacterial sinusitis caused by bacteria that resist penicillin, as described in the approved product labeling. Full prescribing information is available here.

The CNPV recognition, which does not ensure approval, comes at a moment when America's pharmaceutical supply chain remains precariously dependent on foreign manufacturers for critical medicines. USAntibiotics' world-class, 394,000-square-foot production facility in Bristol, Tennessee, has the capacity to produce enough amoxicillin products to meet 100% of the nation's demand for these essential medications. In the agency's FDA Direct podcast, Commissioner Makary said Friday of USAntibiotics' production of amoxicillin and Augmentin: "Thank you for making it in the United States of America."

About USAntibiotics

USAntibiotics is the only U.S. manufacturer of amoxicillin and amoxicillin clavulanate, commonly known as Amoxil® and Augmentin®. Based in Bristol, Tennessee, the company operates a world-class, 394,000-square-foot antibiotic production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare® family of companies. For more information, visit www.us-antibiotics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251022201831/en/

CONTACT: For More Information, Contact:

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA TENNESSEE

INDUSTRY KEYWORD: FDA MANUFACTURING OTHER MANUFACTURING HEALTH PHARMACEUTICAL

SOURCE: USAntibiotics

Copyright Business Wire 2025.

PUB: 10/22/2025 09:00 AM/DISC: 10/22/2025 09:00 AM

http://www.businesswire.com/news/home/20251022201831/en

 

Trending Videos

Salem News Channel Today

Sponsored Links

Trending Videos

On Air & Up Next

  • Best Stocks Now
    12:00PM - 1:00PM
     
    Bill Gunderson provides listeners with financial guidance that is both   >>
     
  • Bloomberg Businessweek
    1:00PM - 2:00PM
     
    Get the latest news from the world of business and finance and the interesting   >>
     
  • Money Pulse
    2:00PM - 2:30PM
     
    Host Dynasti Young and Craig Roberts talk to innovative startups and enduring businesses here in the Bay Area.
     
  • Business By The Bay
    2:30PM - 3:00PM
     
    San Francisco Bay Area has given the world some of the greatest business   >>
     
  • Investor's Edge
    3:00PM - 4:00PM
     
    Gary Kaltbaum is a hard hitting and pull-no-punches host especially when it   >>
     

See the Full Program Guide